At its recent 70th annual meeting, the American Epilepsy Society (AES) highlighted a study focusing on the potential of cannabidiol (CBD) to treat the frequency and severity of seizures in children who have drug-resistant epilepsies. India Globalization Capital (NYSE MKT: IGC), an innovator in developing cannabis-based combination therapies to treat pain and other conditions, is currently applying the revolutionary seizure-treating potential of CBD to another population: domestic pets, and the company is addressing the 5 percent of dogs and just over 2 percent of cats in the United States that experience seizures. “Cannabidiol is the most abundant non-psychoactive cannabinoid found in the cannabis plant. Both anecdotal evidence and pre-clinical research have suggested that CBD may have a broad range of beneficial therapeutic uses in humans and animals including pain mitigation, epileptic seizures and wasting disease eating disorders (cachexia). Animal studies have also shown promise for CBD’s anticonvulsant efficacy in multiple species.”
To view the full article, visit http://nnw.fm/qkMs7
About India Globalization Capital, Inc.
India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions. In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland. For more information, visit http://www.igcinc.us.
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of CBDWire (CBDW). NNB keeps you up-to-date on active US Public Companies complementary to CBDW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
Please see full disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, CO
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com